# Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

> **NCT04355793** · — · NO_LONGER_AVAILABLE · sponsor: **Incyte Corporation**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04355793
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04355793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04355793, "Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04355793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*